**Core Concept**
Metoprolol, a beta-1 selective adrenergic receptor blocker, is preferred over non-selective beta blockers like propranolol in certain patients due to its reduced risk of bronchoconstriction and peripheral vasoconstriction.

**Why the Correct Answer is Right**
Metoprolol's selective beta-1 blockade spares beta-2 receptors in the bronchial tubes, making it a safer choice for patients with asthma or chronic obstructive pulmonary disease (COPD). This selectivity also reduces the risk of peripheral vasoconstriction, which can be beneficial in patients with Raynaud's phenomenon or peripheral vascular disease. Metoprolol's lipophilic nature allows for better penetration into the myocardium, enhancing its beta-blocking effects and reducing its systemic side effects.

**Why Each Wrong Option is Incorrect**
**Option A:** Metoprolol has a longer half-life than propranolol, but this is not the primary reason for its preference in certain patients.
**Option B:** Metoprolol does not have a significantly higher bioavailability than propranolol, making this an incorrect choice.
**Option C:** Metoprolol is not necessarily safer in patients with liver disease, as it is metabolized by the liver and can accumulate to toxic levels in severe cases.

**Clinical Pearl / High-Yield Fact**
When choosing between beta blockers, remember that non-selective beta blockers like propranolol can cause bronchoconstriction and peripheral vasoconstriction, whereas beta-1 selective blockers like metoprolol are safer in patients with respiratory or vascular disease.

**Correct Answer: C.**